Short-term Efficacy Of Raltitrexed Combined Oxaliplatin Chemoembolization For Primary Liver Cancer

Background:To analyze and compare the efficacy and safety of Raltitrexed combined Oxaliplatin and Pirarubicin combined Oxaliplatin intervention on primary liver cancer.Patients and Methods:Between June 2013 to March 2015,120 patients with PLC were enrolled to be treated with one or more cycles of based TACE.Due to follow-up treatment programs change or lost,the number of cases completed short-term efficacy and adverse reactions analysis were 75 cases,study group 39 cases,control group 36 cases,they all were in line with the China Cancer Association liver cancer Professional Committee amendment liver cancer clinical diagnosis standard(Yang,2001).They were treated with three or four cycles,study group 126 cycles,control group 121 cycles.The follow-up of living conditions were recorded for all patients.Statistical analysis was onducted with SPSS 18.0 software.Count data using x2 test,measurement data using t test,with P<0.05 was considered statistically significant.Results:75 cases were successfully treated with at least three times TACE treatment,and totally 247 times treatments were successfully completed.Study group 39 cases,and totally 126 times treatments;control group 36 cases,and totally 121 times treatments.The curative effect was evaluated in the 4-6 weeks after last treatament,the disease control rate of study group was 92.31%.In control group,the disease control rate was 83.33%.Differences between the two groups were not statistically significant(P>0.05).The content of AFP dropped by over 50%in 7 cases(18.0%)in study group.The content of AFP dropped by over 50%in 13 cases(36.1%)in control group.Differences between the two groups were not statistically significant(P>0.05).In the study group,postoperative fever(after 3 days)?postoperative pain(no pain before surgery +postoperative pain compared with preoperative pain exacerbated)?gastrointestinal reaction(nausea,ventosity)?lower serum albumin(??Class ?)were lower than in the control group,the differences between the two groups were statistically significant.Neurological toxicity had not happened in the two groups.According to comparing the preoperative and postoperative liver and kidney function,blood results in the two groups,they confirmed the study group preoperative total bilirubin,direct bilirubin,serum albumin,ALP,BUN,CR were higher,ALT,AST,y-GT,WBC,HB were lower than in the control group;the study group postoperative serum albumin,BUN,CR were higher,total bilirubin,direct bilirubin,ALT,AST,ALP,?-GT,WBC,HB were lower than in the control group,the differences were statistically significant.In the study group,postoperative total bilirubin,direct bilirubin,ALT,AST were higher than preoperative;serum albumin,HB were lower than preoperative,the differences were statistically significant.In the control group,postoperative total bilirubin,direct bilirubin,ALT,AST,ALP,WBC were higher than preoperative;postoperative serum albumin,HB were lower than preoperative,the differences were statistically significant.Other serious adverse reactions,bleeding and other complications did not occur in two groups.Conclusion:Compared with the control group,primary liver cancer treated with Raltitrexed combined Oxaliplatin has a less adverse reaction,no difference between the recent curative effect,the long-term curative effect remains to be seen.